Log in to search using one of your social media accounts:


How this biotech plans to go up against big pharma with its eye disease products

Shankar Musunuri has spent time in both the pharmaceutical world and the biotech arena – after 15 years at Pfizer (NYSE:PFE), he went on to launch several biotech start-ups. As co-founder, chairman &chief executive of Ocugen, he is looking to bring eye disease products to the patients that big pharma’s drugs have left out. “There’s so much unmet need when you look into retinal diseases,” Musunuri said. Get the full story at our sister site, Drug Delivery Business News. The post How this biotech plans to go up against big pharma with its eye disease products appeared first on MassDevice.
Source: Mass Device - Category: Medical Devices Authors: Tags: Biotech Optical/Ophthalmic Pharmaceuticals Research & Development Wall Street Beat Allergan Massachusetts Eye & Ear Infirmary ocugen Pfizer Regeneron Roche Shire Plc. Source Type: news

Related Links:

Canada's government health agency said on Tuesday it is working with the U.S. Food and Drug Administration to address a shortage of Mylan N.V.'s EpiPen emergency allergy antidote that has hit several countries outside of the United States, where it is manufactured.Reuters Health Information
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Medscape Today News Source Type: news
Authors: Md LC, Md JY Abstract BACKGROUND: Artemisia and Humulus pollen are the two most important aeroallergens of autumn allergies in North China. Cross-sectional data in 2001 have shown that allergic rhinitis often preceded or occurred at the same time as asthma in patients with autumn pollinosis in North China. OBJECTIVE: We used this cross-sectional data to investigate the association of serum specific IgE (sIgE) levels to Humulus and/or Artemisia pollen with the onset of asthma in patients with autumn pollen-induced allergic rhinitis. METHODS: 1096 patients with autumn pollinosis were face-to-face int...
Source: Journal of Asthma - Category: Respiratory Medicine Tags: J Asthma Source Type: research
(MedPage Today) -- But study design criticized by journal editor
Source: MedPage Today Allergy - Category: Allergy & Immunology Source Type: news
Conclusions. To our knowledge, we report the largest cohort of iodine allergic patients undergoing ERCP ever published. These results suggest that ERCP-related CM adverse reactions are very rare even among patients at risk for CM reaction. PMID: 29666785 [PubMed - in process]
Source: Canadian Journal of Gastroenterology - Category: Gastroenterology Tags: Can J Gastroenterol Hepatol Source Type: research
Authors: Tom WL Abstract Many children with atopic dermatitis also have an allergy to one or more foods, but the presence of these two conditions in an individual does not necessarily indicate a causal link between them. Testing and interpretation, sometimes with specialist consultation, may be required to discern whether food allergy is present in a child with atopic dermatitis and-if it is present-whether the food is triggering or exacerbating signs and symptoms of atopic dermatitis. Recent milestone trials have demonstrated that early introduction of peanuts can reduce the development of peanut allergy in at-ris...
Source: Seminars in Cutaneous Medicine and Surgery - Category: Dermatology Tags: Semin Cutan Med Surg Source Type: research
Allergan (NYSE: AGN) today confirmed that it’s in the running to acquire Shire (NSDQ:SHPGY), which rejected a $63 billion offer from Takeda Pharmaceutical (TYO:4502). Dublin-based Allergan, which is in the process of slashing 1,400 jobs from its payroll and exploring “strategic actions,” said there’s no guarantee it will make an offer for Shire. Get the full story at our sister site, Drug Delivery Business News. The post Allergan, Takeda spar for Shire appeared first on MassDevice.
Source: Mass Device - Category: Medical Devices Authors: Tags: Mergers & Acquisitions Pharma Wall Street Beat Allergan Spire Corp. Takeda Pharmaceuticals Source Type: news
Authors: Dodig S, ńĆepelak I Abstract The initial laboratory approach in the diagnosis of allergies is to detect the type of allergic reaction, i.e. whether the patient's allergy is mediated by immunoglobulin E (IgE) or not. For this purpose, the concentration of total serum IgE (tIgE) and specific IgE (sIgE) are determined. Progress in laboratory diagnostics is the use of component-resolved diagnosis (CRD) which implies determination of sIgE against purified native and recombinant allergenic molecules. Component-resolved diagnosis is used in laboratory practice as singleplex and multiplex assays. The choice of all...
Source: Biochemia Medica - Category: Biochemistry Tags: Biochem Med (Zagreb) Source Type: research
Shire plc, one of the largest drugmakers in Massachusetts, disclosed on Thursday that it rejected a $60 billion takeover offer from Takeda last week on the grounds that the bid was too low. Allergan, another large pharmaceutical company based in Ireland, separately announced that it was considering making an offer for Shire. Takeda first announced on March 28 that it was considering an acquisition of Shire (Nasdaq: SHPG), which is headquartered in Ireland but has its U.S. headquarte rs in Lexington,…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news
Australia-headquartered Mayne Pharma Group Limited (ASX: MYX) has grown its headcount in North Carolina by 167 employees since June 2015. Mayne Pharma closed on a roughly $650 million generics buy from Teva Pharmceuticals Industries Limited (NYSE: TEVA) and Allergan (NYSE: AGN) back in 2016. And earlier this week, Mayne Pharma officially opened the doors of a new $80 million manufacturing facility in Greenville. The Australian compa ny also has its U.S. base at a commercial office in Raleigh.  In…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Source Type: news
This study was aimed to evaluate whether ROS could modulate Th2-type inflammation in keratinocytes. Allergen and non-allergen was tested in modulating Th2-type inflammation. Materials: For experiments, normal human epidermal keratinocytes (NHEKs) were treated with an allergen (HDM) and non-allergen (compound 48/80, C48/80) under the same condition.
Source: Journal of Investigative Dermatology - Category: Dermatology Authors: Tags: Clinical Research: Epidemiology of Skin Diseases Source Type: research
More News: Allergy | Biotechnology | Medical Devices | Opthalmology | Pfizer | Pharmaceuticals | Vitamin A